Prostate specific antigen (PSA) kinetic as a prognostic factor in metastatic prostate cancer receiving androgen deprivation therapy: systematic review and meta-analysis

Aim: Metastatic prostate cancer (mPCa) has a poor outcome with median survival of two to five years. The use of androgen deprivation therapy (ADT) is a gold standard in management of this stage.  Aim of this study is to analyze the prognostic value of PSA kinetics of patient treated with hormonal th...

Descripción completa

Detalles Bibliográficos
Autores principales: Afriansyah, Andika, Hamid, Agus Rizal Ardy Hariandy, Mochtar, Chaidir Arif, Umbas, Rainy
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Systematic Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964636/
https://www.ncbi.nlm.nih.gov/pubmed/29904592
http://dx.doi.org/10.12688/f1000research.14026.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5964636/
https://www.ncbi.nlm.nih.gov/pubmed/29904592
http://dx.doi.org/10.12688/f1000research.14026.1

Ejemplares similares